Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice

Gene Therapy volume 6, pages 1751–1758 (1999)Cite this article

Abstract

Replication-competent, attenuated mutants of herpes simplex virus type 1 (HSV-1) have been shown to be efficacious for tumor therapy. However, these studies did not address the consequences of prior exposure to HSV, as will be the case with many patients likely to receive this therapy. Two strains of mice, A/J and BALB/c, were infected with wild-type HSV-1 by intraperitoneal injection and the immune response was determined by plaque reduction assay for neutralizing antibody and ELISA for IgG and IgM. Syngeneic tumors, N18 neuroblastoma and CT26 colon carcinoma, were implanted subcutaneously in HSV-1 seropositive and naive A/J and BALB/c mice, respectively. Established tumors were subsequently treated intratumorally with a multi-mutated HSV-1, G207. G207 inhibited tumor growth to a similar extent whether the mice were seropositive or not. We next examined the effect of multiple intratumoral inoculations of a 10-fold lower dose of G207 on tumor growth. In the multiple treatment group (biweekly for 3 weeks), 75% of tumors were cured, whereas no cures were seen in the single treatment group. We conclude that HSV seropositivity should not deleteriously affect the efficacy of G207 tumor therapy, and multiple inoculations of virus should be considered for clinical evaluation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Whitley RJ . Herpes simplex viruses In: Fields BN, Knipe DM, Howley PM (eds) . Fields Virology, third edition, vol. 2 Lippincott-Raven: Philadelphia 1996 pp 2297–2342

    Google Scholar 

  2. Mester JC, Rouse BT . The mouse model and understanding immunity to herpes simplex virus Rev Infect Dis 1991 13: S935–S945

    Article  PubMed  Google Scholar 

  3. Meignier B, Longnecker R, Roizman B . In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents J Infect Dis 1988 158: 602–614

    Article  CAS  PubMed  Google Scholar 

  4. Burke RL . Contemporary approaches to vaccination against herpes simplex virus Curr Top Microbiol Immunol 1992 179: 137–158

    CAS  PubMed  Google Scholar 

  5. McDermott MR et al. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2 J Virol 1984 51: 747–753

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Halford WP, Veress LA, Gebhardt BM, Carr DJJ . Innate and acquired immunity to herpes simplex virus type 1 Virology 1997 236: 328–337

    Article  CAS  PubMed  Google Scholar 

  7. Walker J, Leib DA . Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function Vaccine 1998 16: 1–5

    Article  CAS  PubMed  Google Scholar 

  8. Corey L, Reeves WC, Holmes KK . Cellular immune response in genital herpes simplex virus infection New Engl J Med 1978 299: 986–991

    Article  CAS  PubMed  Google Scholar 

  9. Ashley R, Benedetti J, Corey L . Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes J Med Virol 1985 17: 153–166

    Article  CAS  PubMed  Google Scholar 

  10. Whitley RJ, Kimberlin DW, Roizman B . Herpes simplex viruses Clin Infect Dis 1998 26: 541–553

    Article  CAS  PubMed  Google Scholar 

  11. Eberle R, Mou SW, Zaia JA . The immune response to herpes simplex virus: comparison of the specificity and relative titers of serum antibodies directed against viral polypeptides following primary herpes simplex virus type 1 infections J Med Virol 1985 16: 147–162

    Article  CAS  PubMed  Google Scholar 

  12. Buchman TG, Roizman B, Nahmias AJ . Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA J Infect Dis 1979 140: 295–304

    Article  CAS  PubMed  Google Scholar 

  13. Lodmell DL, Niwa A, Hayashi K, Notkins AL . Prevention of cell-to-cell spread of herpes simplex virus by leukocytes J Exp Med 1973 137: 706–720

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Lopez C, Arvin AM, Ashley R . Immunity to herpesvirus infections in humans. In: Roizman B, Whitley RJ, Lopez C (eds) . The Human Herpesviruses Raven: New York 1993 397–425

    Google Scholar 

  15. Mineta T et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nature Med 1995 1: 938–943

    Article  CAS  PubMed  Google Scholar 

  16. Yazaki T, Manz HJ, Rabkin SD, Martuza RL . Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1 Cancer Res 1995 55: 4752–4756

    CAS  PubMed  Google Scholar 

  17. Toda M, Rabkin SD, Martuza RL . Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1 Hum Gene Ther 1998 9: 2177–2185

    Article  CAS  PubMed  Google Scholar 

  18. Toda M, Rabkin SD, Kojima H, Martuza L . Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity Hum Gene Ther 1999 10: 385–393

    Article  CAS  PubMed  Google Scholar 

  19. Chou J, Kern ER, Whitley RJ, Roizman B . Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture Science 1990 250: 1262–1266

    Article  CAS  PubMed  Google Scholar 

  20. Goldstein DJ, Weller SK . Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensible for virus growth and DNA synthesis: isolation and characterization of an ICP6 1acZ insertion mutant J Virol 1988 62: 196–205

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Nguyen LH, Knipe DM, Finberg RW . Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection J Virol 1992 66: 7067–7072

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Morrison LA, Knipe DM . Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1 Virology 1997 239: 315–326

    Article  CAS  PubMed  Google Scholar 

  23. Morrison LA, Knipe DM . Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection J Virol 1994 68: 689–696

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Knoblich A, Gortz J, Harle-Grupp V, Falke D . Kinetics and genetics of herpes simplex virus-induced antibody formation in mice Infect Immun 1983 39: 15–23

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Kahlon J, Lakeman FD, Ackermann M, Whitley RJ . Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection J Clin Microbiol 1986 23: 725–730

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Zawatzky R, Hilfenhaus J, Marcucci F, Kirchner H . Experimental infection of inbred mice with herpes simplex virus type 1. I. Investigation of humoral and cellular immunity and of interferon induction J Gen Virol 1981 53: 31–38

    Article  CAS  PubMed  Google Scholar 

  27. Lopez C . Genetics of natural resistance to herpesvirus infections in mice Nature 1975 258: 152–153

    Article  CAS  PubMed  Google Scholar 

  28. Fearon ER et al. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene Cancer Res 1988 48: 2975–2980

    CAS  PubMed  Google Scholar 

  29. Plautz GE et al. Immunotherapy of malignancy by in vivo gene transfer into tumors Proc Natl Acad Sci USA 1993 90: 4645–4649

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Toda M, Martuza RL, Kojima H, Rabkin SD . In situ cancer vaccination: a defective IL-12 defective vector/replication-competent herpes simplex virus vector combination induces local and systemic antitumor activity J Immunol 1998 160: 4457–4464

    CAS  PubMed  Google Scholar 

  31. Dai Y et al. Cellular and humoral immune response to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression Proc Natl Acad Sci USA 1995 92: 1401–1405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pelner L, Fowler GA, Hauts HC . Effects of concurrent infections and their toxins on the course of leukemia Act Med Scand 1958 338 (Suppl.): 1–47

    Google Scholar 

  33. Bluming AZ, Ziegler JL . Regression of Burkitt’s lymphoma in association with measles infection Lancet 1971 2: 105–106

    Article  CAS  PubMed  Google Scholar 

  34. Lindenmann J, Klein P . Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus J Exp Med 1967 126: 93–108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sinkovics J, Horvath J . New developments in the virus therapy of cancer: a historical review Intervirology 1993 36: 193–214

    Article  CAS  PubMed  Google Scholar 

  36. Kapoor AK, Nash AA, Wildy P . Pathogenesis of herpes simplex virus in B cell suppressed mice: the relative roles of cell-mediated and humoral immunity J Gen Virol 1982 61: 127–131

    Article  PubMed  Google Scholar 

  37. Kapoor AK et al. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity J Gen Virol 1982 60: 225–233

    Article  CAS  PubMed  Google Scholar 

  38. Mitchell BM, Stevens JG . Neuroinvasive properties of herpes simplex virus type 1 glycoprotein variants are controlled by the immune response J Immunol 1996 156: 246–255

    CAS  PubMed  Google Scholar 

  39. Shimeld C, Hill TJ, Blyth WA, Easty DL . Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system J Gen Virol 1990 71: 681–687

    Article  PubMed  Google Scholar 

  40. Lopez C, O’Reilly RJ . Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay J Immunol 1977 118: 895–902

    CAS  PubMed  Google Scholar 

  41. O’Reilly RJ, Chibbaro A, Anger E, Lopez C . Cell-mediated immune responses in patients with recurrent Herpes Simplex infections. II. Infection-associated deficiency of lymphokine production in patients with recurrent herpes labialis or herpes progenitalis J Immunol 1977 118: 1095–1102

    PubMed  Google Scholar 

  42. Zweerink HJ, Stanton LW . Immune response to herpes simplex virus infections: virus-specific antibodies in sera from patients with recurrent facial infections Infect Immun 1981 31: 624–630

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Posavad CM, Koelle DM, Corey L . High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes J Virol 1996 70: 8165–8168

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Engler H, Zawatzky R, Kirchner H, Armerding D . Experimental infection of inbred mice with herpes simplex virus. IV. Comparison of interferon production and natural killer cell activity in susceptible and resistant adult mice Arch Virol 1982 74: 239–247

    Article  CAS  PubMed  Google Scholar 

  45. Brenner GJ, Cohen N, Moynihan JA . Similar immune response to nonlethal infection with herpes simplex virus-1 in sensitive (BALB/c) and resistant (C57BL/6) strains of mice Cell Immunol 1994 157: 510–524

    Article  CAS  PubMed  Google Scholar 

  46. Herrlinger U et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector Gene Therapy 1998 5: 809–819

    Article  CAS  PubMed  Google Scholar 

  47. Lopez C et al. Correlation between low natural killing of fibroblasts infected with herpes simplex virus type 1 and susceptibility to herpesvirus infections J Infect Dis 1983 147: 1030–1035

    Article  CAS  PubMed  Google Scholar 

  48. Brchm MA, Bonneau RH, Knipe DM, Tevethia SS . Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1 J Virol 1997 71: 3534–3544

    Google Scholar 

  49. Gathery-Segard H et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity J Virol 1998 72: 2388–2397

    Google Scholar 

  50. Juillard V et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector Eur J Immunol 1995 25: 3467–3473

    Article  CAS  PubMed  Google Scholar 

  51. Yang Y, Li Q, Ertl HCJ, Wilson JM . Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses J Virol 1995 69: 2004–2015

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Zabner J et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator ot the nasal epithelium of patients with cystic fibrosis J Clin Invest 1996 97: 1504–1511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Brattain MG et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties Cancer Res 1980 40: 2142–2146

    CAS  PubMed  Google Scholar 

  54. Corbett TH, Griswold DPJ, Peckham JC, Schnabel FMJ . Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure Cancer Res 1975 35: 2434–2439

    CAS  PubMed  Google Scholar 

  55. Hanfelt JJ . Statistical approaches to experimental design and data analysis of in vivo studies Breast Cancer Res 1997 46: 279–302

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Anu Iyer for technical assistance, Paul Johnson for preparation of column purified G207, Dr Joseph T Newsome and the Georgetown University Research Resource Facility staff for assistance with the animals, and Anastasia Ivanova for biostatistical help. This study was supported in part by grants from the National Institutes of Health (NS32677) and Neuro Vir, Inc. Samuel D Rabkin and Robert L Martuza are consultants to Neuro Vir, Inc. which has a license from Georgetown University to commercialize G207.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Molecular Neurosurgery Laboratory, Georgetown University Medical School, Washington DC, USA

    A Chahlavi, S D Rabkin, T Todo, P Sundaresan & R L Martuza

  2. Department of Microbiology and Immunology, Molecular Neurosurgery Laboratory, Georgetown University Medical School, Washington DC, USA

    S D Rabkin

Authors
  1. A Chahlavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S D Rabkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Todo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Sundaresan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R L Martuza
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chahlavi, A., Rabkin, S., Todo, T. et al. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 6, 1751–1758 (1999). https://doi.org/10.1038/sj.gt.3301003

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301003

Keywords

This article is cited by

Search

Advanced search

Quick links